ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MGNX vs CUE // EV/EBITDA & P/E VALUATION

MacroGenics Inc. (NASDAQ) VS. Cue Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: MGNX 3 — CUE 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGNX VS. CUE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MGNX CUE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -14.03% — TIE /fcf-yield <GO>
Operating Margin -48.70% -60.00% +11.30 MGNX /operating-margins <GO>
Net Profit Margin 0.00% -60.00% +60.00 MGNX /net-margins <GO>
Revenue Growth (YoY) -0.30% 180.00% -180.30 CUE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 CUE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 32.4 46.7 -14.30 CUE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $152.9M $151.6M $1.3M MGNX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MGNX REV CUE REV MGNX GROSS % CUE GROSS % MGNX FCF CUE FCF
FY 2025 $149.5M $27.5M 98.0% — -$83.0M -$21.9M
FY 2024 $150.0M $9.3M 98.0% — -$72.1M -$36.4M
FY 2023 $58.7M $5.5M — — -$78.2M -$40.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGNX // BETA —
CUE // BETA —